<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "trastuzumab (HERCEPTIN) inj VIAL>
<dose><value>8</value>
<value>6</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>trastuzumab (HERCEPTIN) inj VIAL</value>
</drugname><strength><value>440 mg</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>DAY 1 of 21. Administer (LOADING DOSE) diluted in 250 mL 0.9% sodium chloride over 90 minutes. Observe patient for a 60 minute period post-infusion.</value>
<value>DAY 1 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride over 60 minutes. Observe patient for a 30 minute period post-infusion. (For subsequent infusions give over 30 minutes if well tolerated. Observation for subsequent infusions not required if well tolerated.) [Cycles 2, 3 &amp; 4]</value>
<value>DAY 1 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride over 90 minutes. Observe patient for a 60 minute period post-infusion. [Cycle 1 ONLY: Loading Dose]</value>
<value>DAY 1 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride over 60 minutes. Observe patient for a 30 minute period post-infusion. (For all  subsequent infusions give over 30 minutes if well tolerated. Observation for subsequent infusions not required if well tolerated. [Cycles 2 - 4]</value>
<value>DAY 1 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride over 30 minutes. (Observation for subsequent infusions not required if previous infusions well tolerated. [Cycles 5 to 17]</value>
</instruction><volume><value></value>
</volume><units><value>mg/kg</value>
</units><additionalnotes><value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week.</value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. If LVEF is WNL and less than 10% decrease from baseline: Continue treatment. If LVEF is WNL and 10 to 15% decrease from baseline: Continue treatment. If LVEF is WLN and greater than 15% decrease from baseline: Hold treatment. If LVEF is 1 to 5% below LLN and less than 10% decrease from baseline: Continue treatment. If LVEF is 1 to 5% below LLN and 10 to 15% decrease baseline: Hold treatment. If LVEF is 1 to 5% below LLN and greater than 15% decrease from baseline: Hold treatment. If LVEF is greater than 5% below LLN and less than 10% decrease from baseline: Continue treatment. If LVEF is greater than 5% below LLN and 10 to 15% decrease from baseline: Hold treatment. If LVEF is greater than 5% below LLN and greater than 15% decrease from baseline: Hold treatment. Resume if criteria for continuation met. Discontinue if 2 consecutive &amp;quot;holds&amp;quot; or a total of 3 &amp;quot;holds&amp;quot; occur.</value>
<value>If ANC is greater than or equal to 1.5 AND Plts are greater than or equal to 100 x 109/L: Give as ordered. If ANC is less than 1.5 OR Plts are less than 100 x 109/L: Delay 1 week. [Part 2: Cycle 1]</value>
<value>If LVEF is WLN and less than 10% decrease from baseline: Continue treatment. If LVEF is WLN and 10 to 15% decrease from baseline: Continue treatment. If LVEF is WLN and greater than 15% decrease from baseline: Hold treatment. If LVEF is 1 to 5% below LLN and less than 10% decrease from baseline: Continue treatment. If LVEF is 1 to 5% below LLN and 10 to 15% decrease baseline: Hold treatment. If LVEF is 1 to 5% below LLN and greater than 15% decrease from baseline: Hold treatment. If LVEF is greater than 5% below LLN and less than 10% decrease from baseline: Continue treatment. If LVEF is greater than 5% below LLN and 10 to 15% decrease from baseline: Hold treatment. If LVEF is greater than 5% below LLN and greater than 15% decrease from baseline: Hold treatment. Resume if criteria for continuation met. Discontinue if 2 consecutive &amp;quot;holds&amp;quot; or a total of 3 &amp;quot;holds&amp;quot; occur.</value>
</additionalnotes><population><value>Fluorouracil, Epirubicin, Cyclophosphamide (FEC) followed by DOCEtaxel &amp; Trastuzumab</value>
<value>Fluorouracil, Epirubicin, Cyclophosphamide (FEC) followed by DOCEtaxel and Trastuzumab. Breast Cancer (NEOADJUVANT Treatment).</value>
<value>DOXOrubicin, Cyclophosphamide (AC) followed by DOCEtaxel and Trastuzumab. Breast Cancer (NEOADJUVANT Treatment).</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3457</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>